Healthcare / BiotechnologyHKSE
$0.09
+0.00 (+1.12%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $36.6M · quality 75.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
63/100
B
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$537M
P/E
4.5x
↓EV/EBITDA
3.7x
↓ROE
22.6%
↑Gross Margin
83.2%
↑Debt/Equity
0.24
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.0%
FCF CAGR
+21.8%
FCF margin
6.2%
FCF / Net income
0.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $586.2M · net income $93.3M · FCF $36.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $586.2M | $586.2M | $553.0M | $484.7M | $440.3M |
| Net Income | $93.3M | $93.3M | $82.8M | $70.9M | $38.5M |
| EBITDA | $124.5M | $124.5M | $113.7M | $93.6M | $61.2M |
| EPS | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
| Gross Margin | 83.2% | 83.2% | 83.4% | 81.0% | 76.1% |
| Operating Margin | 17.1% | 17.1% | 16.3% | 14.1% | 9.6% |
| Net Margin | 15.9% | 15.9% | 15.0% | 14.6% | 8.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.24 | 0.24 | 0.35 | 0.22 | 0.12 |
| Current Ratio | 3.23 | 3.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $36.6M | $36.6M | $28.7M | $39.1M | $20.2M |
| Returns | |||||
| ROE | 22.6% | 22.6% | 25.4% | 27.6% | 19.8% |
| Valuation | |||||
| P/E | 4.50 | 4.50 | 4.44 | 7.12 | 11.15 |
| EV/EBITDA | 3.74 | 3.74 | 3.78 | 4.59 | 5.83 |
| P/B | 1.30 | 1.30 | 1.13 | 1.96 | 2.22 |
| Growth & Yield | |||||
| Revenue Growth | 6.0% | 6.0% | 14.1% | 10.1% | — |
| EPS Growth | 15.6% | 15.6% | 21.6% | 82.0% | — |
| Dividend Yield | 3.5% | 3.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-20.0%
EPS terminal req.
$0.01
Spread vs growth
35.6%
5Y implied EPS CAGR
-9.1%
EPS terminal req.
$0.01
Spread vs growth
24.7%
10Y implied EPS CAGR
-0.0%
EPS terminal req.
$0.02
Spread vs growth
15.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+12.0%
Start / end P/E
6.1x → 5.8x
EPS bridge
0.01 → 0.02
Residual
-1.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.